Vaaka buys Medbase as fund III approaches full deployment

The GP has bought the asset from its Buyout Fund III, which closed in December 2016 at a EUR 225m hard cap. Vaaka partner Ville Koskenvuo said that Fund III is now pretty close to being fully deployed. 

Vaaka also held a final close on Buyout IV in December 2021 at EUR 250m, after just 10 weeks of fundraising. It hasn't yet made any deals from the fund, Koskenvuo said. 

Medbase has annual revenues of around EUR 5m, Koskenvuo confirmed. Its database is already in use in the Nordics, Baltics, DACH, Benelux, Italy and Poland. Vaaka will help to expand its services into new countries in Eastern and Southern Europe. 

The company had been owned by its founders. 

Its best-known databases are Inxbase (drug-drug interactions) and Riskbase (adverse drug interactions).

The company 

Medbase, based in Turku, is a producer of drug-related medical decision-support databases for healthcare professionals. Its purpose as a company is to improve clinical decision-making by expanding access to user-friendly drug information through portals and health information systems in hospitals and pharmacies. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Buyouts
• Finland
• Vaaka Partners Ltd (Formerly Pohjola)